Kidney transplant rejection occurs when the body’s immune system recognizes a new kidney as foreign and attempts to attack it. While modern medicine offers proven treatments to prevent and manage this complication, understanding the available therapies—from standard immunosuppressive drugs to emerging treatments being tested in clinical trials—is essential for protecting transplanted kidneys and improving long-term outcomes.

Understanding Treatment Goals for Transplant Rejection

When someone receives a kidney transplant, their body naturally views this new organ as something that doesn’t belong. The main goal of treatment is to prevent the immune system from damaging the transplanted kidney while maintaining the patient’s overall health. Treatment aims to stop rejection episodes before they cause permanent harm, preserve kidney function over many years, and help patients maintain the best possible quality of life after their transplant.^[1]

The approach to treating kidney transplant rejection depends heavily on several factors. The timing of rejection matters greatly—whether it happens within weeks of surgery or years later changes how doctors respond. The type of rejection also influences treatment choices, as the immune system can attack the kidney through different pathways. Some patients experience what doctors call acute rejection, which develops quickly, while others face chronic rejection, a slower process that unfolds over years. Patient characteristics such as age, other health conditions, and how well they tolerate medications also shape treatment decisions.^[3]

Modern transplant medicine offers both established treatments that medical societies have approved and recommended for decades, as well as new experimental therapies being studied in clinical trials. These standard treatments form the backbone of rejection prevention and management, while research continues into innovative approaches that might offer better outcomes with fewer side effects. About 15 to 20 percent of people who receive a kidney transplant will experience some degree of rejection, making effective treatment strategies crucial for transplant success.^[1]

Standard Treatment for Kidney Transplant Rejection

The cornerstone of preventing and treating kidney transplant rejection involves medications called immunosuppressants, also known as anti-rejection drugs. These medicines work by reducing the activity of the immune system so it doesn’t attack the transplanted kidney. Every person who receives a kidney transplant must take these medications, typically for the rest of their life, because the risk of rejection never completely disappears even though it decreases over time.^[1]

Several specific immunosuppressive drugs are commonly used in kidney transplant recipients. Cyclosporine and tacrolimus are medications that interfere with immune cells called T lymphocytes, which are the main cells that recognize and attack transplanted organs. Another drug, azathioprine, works by preventing immune cells from multiplying rapidly. A similar but newer medication called mycophenolate mofetil also stops immune cells from reproducing. Prednisone, a steroid medication, reduces inflammation throughout the body and suppresses multiple aspects of the immune response.^[6]

When doctors diagnose acute rejection, they typically prescribe higher doses of these medications or add additional drugs to the treatment plan. The most common first-line treatment for acute rejection involves giving high doses of steroid medications. If rejection doesn’t respond to steroids or if the rejection is severe, doctors may use more powerful agents that deplete T cells from the body. One such medication is called Thymoglobulin, which is specifically designed to eliminate the immune cells causing rejection.^[10]

Healthcare providers carefully tailor drug regimens to meet each patient’s individual needs. Usually, patients receive several anti-rejection medications at once because combining drugs that work in different ways provides better protection against rejection. The doses of these medications often change frequently, especially in the first months after transplant, as doctors monitor how well the patient responds and adjust treatment accordingly.^[6]

Because immunosuppressive drugs reduce the body’s natural defenses, they create a delicate balance. Doctors must give enough medication to prevent rejection but not so much that patients become extremely vulnerable to infections. Blood tests are performed regularly to measure the amount of medication in the body, ensuring levels stay within the therapeutic range—not too high to cause excessive side effects and not too low to allow rejection.^[6]

Side effects from immunosuppressive medications vary depending on the specific drugs used and their doses. Common problems include increased susceptibility to infections, as the immune system’s ability to fight germs is reduced. Some patients experience kidney toxicity, high blood pressure, elevated blood sugar levels leading to diabetes, bone thinning, weight gain, and changes in appearance such as excessive hair growth or facial changes. The risk of infection is especially high in the first few months after transplant because higher doses of anti-rejection medications are typically given during this period.^[6]

The duration of immunosuppressive therapy extends throughout a patient’s life as long as the transplanted kidney continues to function. While doses may be reduced over time as the risk of acute rejection decreases, patients cannot safely stop these medications entirely. Even years after transplant, stopping immunosuppression would likely result in chronic rejection and eventual loss of the transplanted kidney.^[1]

For antibody-mediated rejection, a type of rejection caused by antibodies rather than immune cells, standard treatment often includes plasmapheresis. This procedure involves filtering the patient’s blood to remove harmful antibodies that are attacking the kidney. While plasmapheresis is commonly used, medical experts continue to debate how effective it truly is. Other treatments for antibody-mediated rejection include intravenous immunoglobulins, which are preparations of antibodies given through a vein that may help neutralize harmful antibodies or regulate the immune system.^[10]

Additional medications used for antibody-mediated rejection include drugs that target B cells, which are the immune cells that produce antibodies. Anti-CD20 antibodies such as rituximab work by destroying B cells. Some treatment protocols also use complement inhibitors, which block a part of the immune system called the complement cascade that contributes to tissue damage. Proteasome inhibitors, originally developed for treating certain cancers, are also used in some cases to eliminate antibody-producing cells. However, the effectiveness of these treatments remains uncertain and continues to be studied.^[10]

Managing both types of rejection requires optimizing the overall immunosuppressive regimen. Doctors carefully review each patient’s medication adherence, as failure to take medications as prescribed is a common cause of rejection. They also ensure that drug levels in the bloodstream are adequate and adjust medications if needed. Sometimes rejection occurs despite perfect adherence simply because the current drug combination isn’t strong enough for that particular patient’s immune system.^[10]

Treatment in Clinical Trials

While standard immunosuppressive treatments have greatly improved transplant outcomes, researchers continue to explore new therapies that might work better or cause fewer side effects. Clinical trials test promising medications and approaches before they become widely available, and kidney transplant patients sometimes have opportunities to participate in studies of innovative treatments for rejection.

Clinical trials proceed through distinct phases that serve different purposes. Phase I trials focus primarily on safety, testing new drugs in small groups of people to determine safe dosing ranges and identify side effects. Phase II trials expand to larger groups and evaluate whether the treatment actually works—does it prevent rejection or reverse it when it occurs? Phase III trials involve even more patients and compare the new treatment directly against current standard treatments to see if it offers advantages. These carefully designed studies help researchers understand not just whether a treatment works, but how well it works compared to existing options.^[3]

Despite advances in immunosuppression, kidney transplant rejection continues to challenge transplant medicine. New therapies being tested aim to target rejection more precisely while minimizing damage to the patient’s overall immune function. Some experimental treatments focus on specific molecular pathways involved in the rejection process, attempting to block just the parts of the immune system that threaten the kidney while preserving defenses against infections.^[10]

Innovative approaches being studied include therapies that target specific receptors on immune cells, drugs that interfere with the chemical signals immune cells use to communicate, and treatments that attempt to “re-educate” the immune system to tolerate the transplanted kidney. Some trials explore whether certain medications can be used at lower doses or eliminated entirely in carefully selected patients who have had their transplants for many years without rejection, potentially reducing long-term side effects while maintaining graft survival.^[10]

For antibody-mediated rejection specifically, several novel therapies are under investigation. Researchers are testing new types of complement inhibitors that might more effectively block the damage these proteins cause to transplanted kidneys. Other studies examine whether combining multiple treatments—such as antibody removal through plasmapheresis together with drugs that prevent new antibody production—works better than single approaches.^[10]

Some clinical trials investigate biomarkers that could detect rejection earlier, before symptoms appear or before blood tests show obvious problems. Early detection is crucial because treating rejection promptly, before significant damage occurs, generally leads to better outcomes. Tests that can identify rejection at the molecular level, even when the kidney appears to be functioning normally, might allow intervention before permanent harm develops.^[10]

Trial locations vary widely, with studies conducted at major transplant centers throughout the United States, Europe, and other regions including Poland. Patient eligibility for clinical trials depends on many factors including the type and timing of rejection, previous treatments received, other health conditions, and the specific requirements of each study. Transplant teams can inform patients about relevant trials and help determine whether participation might be appropriate.

It’s important to understand that treatments tested in clinical trials are experimental. While some show promise in early studies, others may ultimately prove ineffective or cause unacceptable side effects. Preliminary results mentioned in research publications represent early findings that require confirmation through larger, more rigorous studies. Even when early data suggest a treatment helps—such as improving certain clinical parameters or showing a positive safety profile—these benefits must be proven through complete Phase III trials before the treatment becomes a standard recommendation.

Most common treatment methods

• Immunosuppressive medications
  • Cyclosporine and tacrolimus interfere with T lymphocytes to prevent immune attack on the transplanted kidney
  • Azathioprine and mycophenolate mofetil prevent immune cells from multiplying
  • Prednisone reduces inflammation and suppresses multiple aspects of immune response
  • Multiple drugs are typically combined for better protection
  • Doses are adjusted based on blood tests and patient response
  • Must be taken lifelong to protect the transplanted kidney
• High-dose steroid therapy
  • First-line treatment for acute rejection episodes
  • Rapidly reduces immune system activity attacking the kidney
  • Administered at higher doses than maintenance therapy
• T-cell depleting agents
  • Thymoglobulin eliminates immune cells causing rejection
  • Used for severe or steroid-resistant rejection
  • More powerful than standard immunosuppression
• Plasmapheresis
  • Blood filtering procedure that removes harmful antibodies
  • Used primarily for antibody-mediated rejection
  • Effectiveness continues to be debated among experts
• Intravenous immunoglobulins
  • Antibody preparations given through a vein
  • May help neutralize harmful antibodies or regulate immune system
  • Often used in combination with other treatments for antibody-mediated rejection
• Anti-CD20 antibodies
  • Medications like rituximab that destroy B cells producing antibodies
  • Used for antibody-mediated rejection
  • Target the source of antibody production
• Complement inhibitors
  • Block the complement cascade that contributes to kidney tissue damage
  • Being tested in clinical trials for antibody-mediated rejection
  • Novel therapies under investigation
• Proteasome inhibitors
  • Originally developed for cancer treatment
  • Eliminate cells that produce antibodies
  • Used in some cases of antibody-mediated rejection